Trametinib is an FDA-approved drug for people with certain cancers. The drug attacks specific types of cancer cells with less harm to normal cells and blocks mechanisms that cancer cells use to keep replicating continuously. Researchers will conduct a small, preliminary clinical trial to see if dogs with aggressive cancers also can benefit from treatment with trametinib. The team will determine an optimal dose for dogs that is both safe and effective in turning off tumor growth signals. The team also will test a simple blood test that can be used to quickly if effective drug levels are present in the enrolled patients. If successful, findings will help inform studies in larger population of dogs with aggressive cancers.
Grant amount awarded
University of Wisconsin-Madison
David M. Vail, DVM